VISION
My Medicine
From Disease- to Humanity-care
Takebe Lab will move medicine into the new dimension so-called “My Medicine”, that pushes humanity towards a better life.
By bringing research and innovation, we’re dedicated to evolving, alleviating and treating humanity today and in the future. Our lab commits to nurture the respect, integration, visualization and sharing in our diverse community.
RESEARCH THEMES
Self-organized generation of multi-zonal liver organoids from pluripotent stem cells
Spearheading research into the development of Zonal Liver Organoids using Molecular and Computational Biology.
Dual role of TM6SF2 E167K in human hepatic steatosis and metabolic dysfunction
By in vitro reconstructing the pathogenesis of fatty liver and diabetes caused by the TM6SF2 mutation, we aim to elucidate the mechanism of pathogenesis.
Minna no KANZO Research
Minna no KANZO Research is a citizen science hub operated by our satellite lab at Miraikan, collecting data on non-alcoholic fatty liver disease (NAFLD) in the Japanese population. We are continuously recruiting participants through the following link.
Clinical development of universal tandem-optimized hepatocyte column with apehresis
We are developing the UTOpiA® SYSTEM (Universal Tandem Optimized iHLC with Adacolumn), a novel organoid therapy device for the treatment of acute liver failure. This system is based on our unique stem cell and organoid technology, which features dramatically enhanced metabolic and synthetic functions.
RELATED LINKS
EVA Therapeutics, Inc.
The EVA technology is the foundation of
our company and its lead project is the intra-rectal delivery of a liquid form of O2 (oxygen)with perfluorocarbon. EVA Therapeutics, Inc is a certified spin-out venture from Tokyo Medical and Dental University.
STELLAR SCIENCE FOUNDATION
To create a scientific research ecosystem, a mechanism that will enable the accelerated and sustained creation of discoveries and inventions beyond imagination that will make a quantum leap forward in the world.
OrsoBio, Inc.
Developing first-in-class therapies to treat patients with metabolic disorders including diabetes, severe dyslipidemias, and more.
Open Medical Lab, Inc.
Developing first-in-class therapies to treat patients with metabolic disorders including diabetes, severe dyslipidemias, and more.